Humana Inc. (NYSE:HUM) Receives $285.68 Average PT from Analysts

Shares of Humana Inc. (NYSE:HUM) have earned an average rating of “Hold” from the twenty-four ratings firms that are presently covering the stock, MarketBeat Ratings reports. Nineteen research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $285.68.

A number of research analysts recently issued reports on the company. Morgan Stanley dropped their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. TD Cowen raised their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Finally, Truist Financial lifted their price objective on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th.

Humana Price Performance

Shares of NYSE HUM opened at $270.91 on Monday. The stock’s 50-day moving average is $271.11 and its two-hundred day moving average is $287.34. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a market cap of $32.68 billion, a price-to-earnings ratio of 27.23, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts forecast that Humana will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.31%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Humana

Hedge funds and other institutional investors have recently made changes to their positions in the business. Creative Financial Designs Inc. ADV grew its position in shares of Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares during the period. Ashton Thomas Securities LLC purchased a new position in shares of Humana in the 3rd quarter worth about $31,000. Your Advocates Ltd. LLP lifted its stake in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. FPC Investment Advisory Inc. purchased a new stake in shares of Humana during the 4th quarter worth about $27,000. Finally, Centricity Wealth Management LLC acquired a new stake in Humana during the 4th quarter worth approximately $30,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.